Achievement of a milestone in the global Phase III registration trial IZABRIGHT-Lung02 has triggered a USD 250 million near-term milestone payment to SystImmune, Inc. under its collaboration with Bristol Myers Squibb

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

Sep 23, 2026